FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Tirzepatide was on the FDA’s drug shortage ... and they have customers that maybe have been getting it from the compounding ...

The FDA issued a warning letter to ProRx, a compounding facility in Exton, Penn., after an inspection raised serious concerns regarding the safety and compliance of its drug products. The facility, ...

Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...

chief advocacy officer for trade group Alliance for Pharmacy Compounding. But the group's members are still reporting that "there's a real lack of availability" of tirzepatide, she said.

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

With tirzepatide and its Novo Nordisk rival ... Late last month, Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said in a statement that the FDA decision was “not necessarily ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and ...

tirzepatide. The FDA declined to comment. The Outsourcing Facilities Association, which brought the lawsuit along with a Texas compounding pharmacy did not immediately respond to requests for comment.

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Tirzepatide, however ... the chief advocacy officer at the Alliance for Pharmacy Compounding. For patients with a severe fear of needles or allergies to inactive ingredients in injectable ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...